147 related articles for article (PubMed ID: 3791306)
1. Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer.
Ashford R; Priestman T; Mott T; Bottomley JM
Cancer Immunol Immunother; 1986; 23(3):217-9. PubMed ID: 3791306
[TBL] [Abstract][Full Text] [Related]
2. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study.
Abdulhay G; DiSaia PJ; Blessing JA; Creasman WT
Am J Obstet Gynecol; 1985 Jun; 152(4):418-23. PubMed ID: 4040329
[TBL] [Abstract][Full Text] [Related]
3. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer.
Walters RS; Theriault RL; Booser DJ; Esparza L; Hortobagyi GN
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):185-7. PubMed ID: 8770774
[TBL] [Abstract][Full Text] [Related]
5. [Breast cancers, apparently non-metastatic, treated by prior chemotherapy and radiotherapy, combined with or without excision surgery. Preliminary results].
Touboul E; Lefranc JP; Blondon J; Guerin RA
Bull Cancer; 1988; 75(6):523-31. PubMed ID: 2843249
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Sarna GP; Figlin RA
Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of locally advanced breast cancer: review and guidelines.
Swain SM; Lippman ME
Oncology (Williston Park); 1989 Jan; 3(1):21-8; discussion 28-30, 34. PubMed ID: 2701401
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
9. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
10. An overview of contemporary management of breast carcinoma.
Suhrland LG
Obstet Gynecol Clin North Am; 1987 Sep; 14(3):783-96. PubMed ID: 3323974
[TBL] [Abstract][Full Text] [Related]
11. Management of locally advanced and inflammatory carcinoma of the breast.
Ackland SP; Bitran JD; Dowlatshahi K
Surg Gynecol Obstet; 1985 Oct; 161(4):399-408. PubMed ID: 3901356
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy of breast cancer.
Hortobagyi GN; Buzdar AU; Ames FC; Blumenschein GR; Montague ED
Prog Clin Biol Res; 1985; 201():105-16. PubMed ID: 4095105
[No Abstract] [Full Text] [Related]
13. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemotherapy in the treatment of inflammatory breast cancer.
Keiling R; Guiochet N; Calderoli H; Hurteloup P; Krzisch C
Prog Clin Biol Res; 1985; 201():95-104. PubMed ID: 4095121
[No Abstract] [Full Text] [Related]
15. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.
Goldhirsch A; Gelber RD; Castiglione M
Ann Oncol; 1990; 1(3):183-8. PubMed ID: 2261364
[TBL] [Abstract][Full Text] [Related]
16. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
[TBL] [Abstract][Full Text] [Related]
17. Human lymphoblastoid interferon (IFN-alpha-N1) plus doxorubicin, cyclophosphamide, and cisplatin in the treatment of advanced epithelial ovarian malignancies. A phase I-II study of the Gynecologic Oncology Group.
DiSaia PJ; Gillette P
Am J Clin Oncol; 1991 Feb; 14(1):71-4. PubMed ID: 1987744
[TBL] [Abstract][Full Text] [Related]
18. Interferon therapy for renal cell carcinoma.
Muss HB
Semin Oncol; 1987 Jun; 14(2 Suppl 2):36-42. PubMed ID: 3589703
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
20. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G; Sniecinski I; Odom-Maryon T; Nowicki B; Chow W; Hamasaki V; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Tetef M; Molina A; Berenson RJ; Forman SJ; Doroshow JH
Blood; 1997 Mar; 89(5):1521-8. PubMed ID: 9057632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
